Merck Keytruda formulations undergo FDA priority review for bladder cancer

Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...

ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC

"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...
CURE

Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression

IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The ...

2 Beaten-Down Stocks to Buy and Hold for the Next Decade

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
TMCnet

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based ...
BioSpace

Moderna Claims Early Victory for Cancer Antigen in Melanoma

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL / ...